Cover Image
市場調查報告書

細胞毒性藥物遞輸

Cytotoxic Drug Delivery

出版商 Greystone Research Associates 商品編碼 300589
出版日期 內容資訊 英文
商品交期: 最快1-2個工作天內
價格
Back to Top
細胞毒性藥物遞輸 Cytotoxic Drug Delivery
出版日期: 2014年05月01日 內容資訊: 英文
簡介

法規當局、產業,由暗示暴露和健康上問題的因果關係的資料所推動,致力於製作保護看護者、患者不暴露於偶發、2次性細胞毒性藥的規格、規範設計。

本報告提供細胞毒性藥物遞輸市場相關調查,主要市場區隔、可定址市場,製劑的主要的治療需求的促進要素,商業化、開發階段所採用的設計因素、技術,市場佔有率、產品的地位,市場參與企業和那個經營模式,及經濟、技術、規定因素的影響等的相關分析,為您概述為以下內容。

摘要整理

  • 治療趨勢、課題
  • 注射/點滴型抗癌症藥
  • 藥物包裝、給藥技術
  • 封閉式托曳傳輸:促進要素
  • 競爭情形
  • 風險因素

細胞毒性藥物傳輸系統:目前世代

  • 主要的系統設計因素
  • 人因工程/人體工學
  • 材料選擇上的課題
  • 藥物的重組與稀釋
  • 癌症治療藥的安全性
  • 癌症治療藥的給藥和用量
  • 每藥物的用量設定和個人的用量設定

封閉式藥物傳輸的商業性設備的評估、市場資料

  • FDA認證產品
  • 商業化FDA未認證產品
  • 封閉式藥物傳輸組件的供應商

市場因素

  • 法律規章上的課題
  • 看護者的適合性
  • 複雜的層級、可用性
  • 醫療經濟學
  • 經營模式、策略

市場評估與預測

  • 北美
  • 歐洲
  • 亞洲
  • 其他地區市場

企業簡介

目錄
Product Code: CYT485F

The administration of drugs deemed hazardous to humans has been receiving increasing amounts of scrutiny in recent years as the dangers of these substances become more clearly understood. For caregivers and their patients, the therapeutic area that is at the forefront of attempts to mitigate exposure to cytotoxic drugs is clinical oncology, a field that - in spite of promising new drugs based on therapeutic antibodies - continues to rely heavily on antineoplastics, a class that includes alkylating agents and antimetabolites, to treat a wide range of cancers. Regulatory and industry efforts to create standards and procedures designed to protect workers and patients from accidental and incidental exposure to cytotoxics are being driven by data that suggests a causal link between exposure and health issues.

Highlights

  • What are the key segments and addressable markets that comprise the market for cytotoxic drug delivery?
  • What are the major therapeutic demand drivers for cytotoxic drug therapeutics?
  • What are the design factors and technologies that are being used in commercial and development-stage closed drug transfer systems?
  • What is the market share and product position in the market and what will it look like in 2018?
  • Who are the companies behind the current generation of cytotoxic transfer solutions and what are their business models?
  • What is the role of pharma-device alliances and design partnerships in the commercialization and market access of new and emerging closed drug transfer systems?
  • What is the impact of economic, technology, and regulatory factors?

Table of Contents

Executive Summary

The Executive Summary

  • Therapeutic Trends and Issues
  • The Administration of injectable/Infusable Antineoplastics
  • Drug Packaging and Administration Technology
  • Closed Drug Transfer - Driving Forces
  • Competitive Landscape
  • Risk Factors

Cytotoxic Drug Transfer Systems - The Current Generation

  • Key System Design Elements
  • Human Engineering/Ergonomics
  • Material Selection Issues
  • Drug Reconstitution and Dilution
  • Oncology Therapeutics Medication Safety
  • Oncology Drug Administration and Dosing
  • Drug-Specific Dosing Modification and Individualized Dosing

Closed Drug Transfer Commercial Device Assessments & Market Data

  • FDA Approved Products
  • Commercialized Non-FDA Approved Products
  • Closed Drug Transfer Component Suppliers

Market Factors

  • Regulatory Issues
  • Caregiver Compliance
  • Level of Complexity and Ease of Use
  • Healthcare Economics
  • Business Models and Strategies

Market Assessments and Forecasts

  • North America
  • Europe
  • Asia
  • Other Geographic Markets

Company Profiles

Back to Top